Troleandomycin

Troleandomycin

SCHEMBL125070

CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrpmArpmBrpmCrpmDrpmE2rpmFrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsU

The experimentally established mechanism targets of Troleandomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 13/20 1.00
USP2 O75604 4/20 1.00
ABCB1 P08183 3/20 1.00
LMNA P02545 2/20 0.71
PGR P06401 1/20 0.40
HTR1A P08908 1/20 0.40
DRD1 P21728 1/20 0.40
SLC6A2 P23975 1/20 0.40
OPRM1 P35372 1/20 0.40
DRD3 P35462 1/20 0.40
SLC6A3 Q01959 1/20 0.40
SLCO1B3 Q9NPD5 2/20 0.38
SLCO1B1 Q9Y6L6 2/20 0.38
MLNR O43193 4/20 0.37
KCNH2 Q12809 4/20 0.36
MAPK1 P28482 2/20 0.36
AR P10275 1/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALB P02768 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Troleandomycin SCHEMBL125071 1.00 CYP3A4 (1.00) CYP3A4USP2ABCB1LMNAPGR
Troleandomycin SCHEMBL29470683 1.00 CYP3A4 (1.00) CYP3A4USP2ABCB1LMNAPGR
Troleandomycin SCHEMBL664623 1.00 CYP3A4 (1.00) CYP3A4USP2ABCB1LMNAPGR
Troleandomycin SCHEMBL28198745 0.97 CYP3A4 (0.94) CYP3A4USP2ABCB1LMNAPGR
Troleandomycin SCHEMBL3065803 0.89 CYP3A4 (0.79) CYP3A4USP2ABCB1LMNAPGR
SCHEMBL15944213 0.89 CYP3A4 (0.80) CYP3A4USP2ABCB1LMNAPGR
Diproleandomycin SCHEMBL2109038 0.88 CYP3A4 (0.78) CYP3A4USP2ABCB1LMNAPGR
SCHEMBL26436882 0.84 CYP3A4 (0.72) CYP3A4USP2ABCB1LMNAPGR
Oleandomycin SCHEMBL3716 0.83 CYP3A4 (1.00) CYP3A4USP2ABCB1LMNASLCO1B3
Oleandomycin SCHEMBL10028439 0.83 CYP3A4 (1.00) CYP3A4USP2ABCB1LMNASLCO1B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 15564 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139860-A1 PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS CENTRE FOR DIGESTIVE DISEASES (AU) 2026-05-21 US claimed
US-12629363-B2 Prophylaxis and treatment of angioedema PHARVARIS GMBH (CH) 2026-05-19 US claimed
US-12616708-B2 Methods for treating pulmonary non-tuberculous mycobacterial infections INSMED INCORPORATED (US) 2026-05-05 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260097039-A1 METHODS FOR TREATING A FATTY LIVER DISEASE MADRIGAL PHARMACEUTICALS INC (US) 2026-04-09 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
US-20260034154-A1 METHODS FOR TREATING NEWLY DIAGNOSED MYCOBACTERIUM AVIUM COMPLEX LUNG INFECTIONS INSMED INCORPORATED (US) 2026-02-05 US claimed
EP-4680248-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM Topelia Aust Limited (ACN 652 771 670) (AU) 2026-01-21 EP claimed
US-20260007719-A1 COMPOSITION FOR INTERMITTENT DOSING OF CALCINEURIN INHIBITORS KLEE TREVOR (US) 2026-01-08 US claimed
EP-4674894-A2 COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES Hemoteq AG (DE) 2026-01-07 EP claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1996011684-A1 METHOD FOR TOPICAL INHIBITION OF THE METABOLIC ACTIVITY OF CYTOCHROME P-450 TWK, INC. (US) 1996-04-25 WO claimed
US-5472954-A Combining cyclodextrin with polymer before adding active material CYCLOPS H.F. (IS) 1995-12-05 US claimed
WO-1995018865-A1 METHOD TO DIAGNOSE AND TREAT ALLERGIC INFLAMMATION NATIONAL JEWISH CENTER FOR IMMUNOLOGY AND RESPIRATORY MEDICINE (US) 1995-07-13 WO claimed
US-5288503-A WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL SRCHEM INCORPORATED (US) 1994-02-22 US claimed
US-5260066-A Cryogel bandage containing therapeutic agent SRCHEM INCORPORATED (US) 1993-11-09 US claimed
US-5051262-A Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby ELAN CORP., P.L.C. (IE) 1991-09-24 US claimed
EP-0273202-A2 Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. Van Scott, Eugene J., Dr. (US) 1988-07-06 EP claimed
US-4726951-A New pharmaceutical forms for administration of medicaments by oral route, with programmed release ELAN CORPORATION P.L.C. (IE) 1988-02-23 US claimed
US-4069322-A Pro-drugs for the improved delivery of certain selected anti-inflammatory steroids INTERX RESEARCH CORPORATION (US) 1978-01-17 US claimed